Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Cyclacel Pharmaceuticals, Inc. (CYCC) Tops Q2 EPS by 8c
August 12, 2014 5:11 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.22), $0.08 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $264 thousand, versus $356 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.
... More